NHS Breast Cancer Drug Wins All Clear

Health officials have approved the first breast cancer drug in a decade for widespread NHS use.

Trial results show eribulin, also known as Halaven can offer three months of additional life compared with other therapies.

Health watchdogs say it should be made available across the NHS in England.